Subscribe to NRx Newsletter

Investor Relations

NRx Pharmaceuticals is a clinical-stage, biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, is an oral, fixed dosed combination of D-cycloserine and lurasidone, which targets the brain’s NMDA receptor. Please click here for more on our clinical trial status.

NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is now traded on the Nasdaq Global Select Exchange.

Stock Data

NRX Pharmaceuticals Inc. (NRXP)
Detailed Quote

Recent News

Recent News (new)

For more news and articles, visit our news page.

Press Release
April 17, 2024

New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections NRX-101 previously...

Press Release
April 15, 2024

Formulation based on prior patents by NRx founder Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration Company expects...

Press Release
April 8, 2024

Data transferred for independent statistical analysis Top-line data expected in April 2024 RADNOR, Pa., April 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx...

Bottom Global Links (above footer)
NRx Communications

Subscribe to the NRx Mailing List